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A B S T R A C T   
Introduction: Niemann-Pick C (NPC) is an autosomal recessive disease due to defective NPC1 or NPC2 proteins 
resulting in endo-lysosomal storage of unesterified cholesterol in the central nervous system and liver. Acute liver 
disease in the newborn period may be self-limited or fatal. 2-hydroxypropyl-β-cyclodextrin (2HPBCD) is a 
cholesterol-binding agent that reduces lysosomal cholesterol storage. We have enrolled 3 infants 0–6 months old 
with direct hyperbilirubinemia due to NPC1 or NPC2 liver disease in a Phase I/II open label clinical trial of 
intravenous 2HPBCD. 
Methods: Infants received intravenous 2HPBCD twice a week for 6 weeks, followed by monthly infusion for 6- 
months. Primary outcome measure was reduction of plasma (3β,5α,6β-trihydroxy-cholan-24-oyl) glycine 
(TCG), a bile acid generated from cholesterol sequestered in lysosome. 
Results: Three participants completed this protocol. A fourth patient received intravenous 2HPBCD under an 
emergency investigational new drug study but later expired from her underlying condition. The three protocol 
patients are living and have improved liver enzymes and TCG. No patient has experienced a drug-related adverse 
event. 
Conclusion: Intravenous 2HPBCD was tolerated in three infants with liver disease due to NPC.   
1. Introduction 
Niemann-Pick disease, type C (NPC) has an incidence of 1 in 120,000 
live births. It results from pathogenic variant of either the NPC1 (~95% 
of cases) or NPC2 genes [1]. The NPC1 protein is a cholesterol trafficking 
protein, so the NPC1 gene mutation results in accumulation of unes-
terified cholesterol and other lipids in lysosomes leading to disease 
involving the central nervous system and peripheral tissues such as the 
liver [1]. NPC has a phenotypic spectrum ranging from infantile death to 
a chronic neurodegenerative disease in adulthood. Most commonly, it is 
characterized by neurodegeneration in early childhood and death in 
adolescence [1]. Individuals with NPC demonstrate progressive central 
nervous system decline including inability to coordinate balance, gait, 
and extremity movements. Liver disease in the newborn/infant period is 
frequently observed. Some patients succumb to progressive liver 
disease, but in many patients the liver disease improves resulting in 
chronic liver disease [1]. 
There is currently no treatment for NPC in the United States, but 
clinical trials are ongoing with 2-hydroxypropyl-beta-cyclodextrin 
(2HPBCD). Here, we report our preliminary experience with intrave-
nous 2HPBCD to treat the infantile liver disease in NPC patients. One 
subject, Patient A, was treated under an emergency investigational new 
drug (IND) study, and three have enrolled in a phase 1/2a, open-label, 
multiple ascending dose trial. The study aims to evaluate whether 
2HPBCD administered intravenously may be safe and effective in 
treating liver disease in NPC infants. 
2. Materials and methods 
Studies were reviewed and approved by the Human Research 
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Protection Office at Washington University in St. Louis School of Med-
icine in St. Louis, Missouri. It was approved by the Federal Drug 
Administration as an Investigational New Drug. All patients underwent 
written, informed consent for the trial and gave permission for inclusion 
in this report. 2HPBCD (Kleptose HPB) was formulated as VTS-270 
(Mallinckrodt Pharmaceutical, Bedminster, NJ). Prior to the approval 
of the open-label clinical trial, a patient with NPC and liver failure 
presented to St. Louis Children's Hospital (SLCH), and was treated under 
an emergency IND. 
2.1. Administration and dosing protocol 
To be enrolled in the study, patients were required to be 0–6 months 
of age, carry a diagnosis of NPC1 or NPC2, and have a hyper-
bilirubinemia. VTS-270 was administered intravenously through a 
peripherally inserted central catheter placed (PICC) place after admis-
sion to the Neonatal Intensive Care Unit (NICU) at St. Louis Children's 
Hospital. VTS-270 was provided as a 200 mg/mL solution and admin-
istered at a rate of 250 mg/kg/h. Dosing for this phase one trial began at 
500 mg/kg. The infusion rate was decreased in 25 mg/kg/h increments 
to 175 mg/kg/h if required. 
Infants remained in the NICU for doses 1 and 2, on standard NICU 
continuous monitoring. 
2.2. Doses 3–18 
Interval between dosing was 4 ± 1 days. IV VTS-270 was adminis-
tered via the central venous line at a rate of 250 mg/kg/h. Rate, vital 
signs (temperature, heart rate, respiratory rate, supine blood pressure, 
and SaO2) and standard neurological checks were conducted as for dose 
1 and 2. These doses were given as an outpatient, within our Pediatric 
Clinical Research Unit. 
2.3. Modifications in the event of toxicity 
If the subject did not tolerate the 500 mg/kg dose, the dose was to be 
decreased to 250 mg/kg. If the subject did not tolerate the 1000 mg/kg 
dose, the dose was to be decreased to 500 or 250 mg/kg. 
2.4. Emergency IND modifications 
The subject treated under the eIND was initiated at 250 mg/kg, and 
sequentially increased to 500 mg/kg, and 1000 mg/kg, when laboratory 
and clinical status did not improve. 
2.5. Assessment of efficacy 
Determination of efficacy was based upon biochemical response of 
plasma biomarkers (e.g., cholestane-3β,5α,6β-triol (C-triol) [2], 7-keto-
cholesterol (7-KC) [2], 3β,5α,6β-trihydroxy-cholan-24-oyl) glycine 
(TCG) [3], and N-palmitoyl-O-phosphocholine-serine (PPCS)) [4]; 
serum aspartate aminotransferase (AST)/alanine aminotransferase 
(ALT) and total and direct bilirubin; and abdominal ultrasound to assess 
changes in liver and spleen volumes. 
2.6. Open-label clinical trial 
For subjects in Phase I of the study, infants were treated twice weekly 
for six weeks. After completion of Phase I, children were then evaluated 
for eligibility to progress to Phase II of the study in which they were 
treated once per month for six months. 
Patients included in the study underwent the following laboratory 
tests: 
2.6.1. Hematology 
complete blood count (CBC) with differential and platelet count, and 
prothrombin time (PT). 
2.6.2. Clinical chemistry 
electrolytes, glucose, blood urea nitrogen (BUN), creatinine, AST, 
ALT, gamma-glutamyl transferase (GGT), alkaline phosphatase, bili-
rubin (direct and total), albumin, calcium, magnesium, phosphorus, 
total protein, and creatine kinase (CK). 
2.6.3. Urinalysis 
protein, blood, leukocytes, glucose, ketones, bilirubin, urobilinogen, 
pH, and specific gravity and microscopic analysis. 
In Phase I, testing occurred at baseline, 2, 4 and 6 weeks. In Phase II, 
testing occurred at baseline, 2, 4, and 6 months. 
Patients also underwent additional research testing of NPC1 specific 
markers including TCG (ref < 13.5 ng/mL), C-triol (ref <0.07 ng/mL), 7- 
KC (ref <0.10 ng/mL), PPCS (ref <0.10 ng/mL) (Phase I: Baseline, 2, 4 
and 6 weeks; Phase II: Baseline, 2, 4 and 6 months.). 
Additional testing for the study included: 
In Phase I: audiological evaluation, specifically, otoacoustic emis-
sions (OAE) without sedation (baseline, 6 weeks) 
Abdominal ultrasound (baseline, 6 weeks) Liver size was determined 
by the liver's midclavicular longitudinal diameter. Organ volumes are 
the product of three long axes (longitudinal, transverse and anterior- 
posterior). 
In Phase II: abdominal ultrasound (6 months) 
Subjects who demonstrated reduction either in TCG or serum bili-
rubin (direct bilirubin or direct bilirubin:total bilirubin ratio) were 
eligible to enter into the second Phase of the study, an open-label Phase 
of six months duration in which IV 2HPBCD was administered monthly 
for a total of six doses. Procedures during the second Phase included a 
monthly intravenous line placement, physical assessment, blood draws 
and urine collection during month 1, 2, 4, and 6, and monthly drug 
administration. 
Primary outcome measure is the efficacy of IV 2HPBCD to reduce 
plasma levels of TCG. Secondary outcome measures include: effect of 
drug on serum transaminases (ALT, AST) and reduction of liver and/or 
spleen volumes. 
3. Results 
The study has enrolled three subjects, and none have withdrawn. 
One additional patient was treated under an eIND for acute liver failure 
before the study opened for enrollment. This patient, Patient A, expired 
from her liver disease. 
3.1. Patient A 
A 38 3/7 weeks post menstrual age (PMA) female born at 2.63 kg 
(Table 1) with birth history significant for intrauterine growth restric-
tion, delayed prenatal care (21 weeks) due to lack of health insurance, 
and family history of a “close” relative with a child who died at 2 months 
of age due to unclear reasons including hepatic failure. Patient A pre-
sented with cholestasis and hepatosplenomegaly (Fig. 1) at <1 week of 
age. Coagulation studies were abnormal. Abdominal ultrasound 
confirmed splenomegaly and revealed a coarse liver, loss of the uniform 
smooth echotexture, with a cavernous hemangioma. Alpha fetoprotein 
(AFP) was elevated at 77,000 ng/mL with repeat value of 92,000 (nl 
<41,687 ng/mL). Sequencing of NPC1 revealed a likely pathogenic 
variant designated as c. 3053 G > A;p.C1168Y [5] and a variant of un-
certain significance (VUS) designated as c.1301C > G; p.P434R [6]. 
The Phase 1/2 clinical trial had not yet opened for enrollment, so a 
single patient emergency treatment was pursued for this baby. At 6 
weeks of life, she underwent her first infusion of 2HPBCD. At 6 weeks 
old prior to initiation of the treatment, the child had hep-
atosplenomegaly, end stage liver disease, ascites, direct hyper-
bilirubinemia, elevated liver enzymes, hypoalbuminemia, and 
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pancytopenia. Her multiple abdominal ultrasounds prior to treatment 
revealed multiple and increasing hypoechoic liver lesions increasing, 
hepatosplenomegaly, ascites, and edematous bowel. Doppler studies did 
not document portal hypertension prior to treatment. She tolerated 
doses at 250 mg/kg, 500 mg/kg, and 1000 mg/kg without adverse 
events. The doses were escalated as she tolerated the medication, and 
her systemic condition worsened. She completed 12 infusions of 
2HPBCD. Her PPCS decreased from 3420 to 1610 (Fig. 1). Downtrending 
of PPCS, which has been used as a marker for NPC severity, has been 
previously been shown to decrease with IV 2HPBCD and potentially 
indicates a reduction of lipid in the liver [2,7,8]. Unfortunately, the 
patient expired prior to undergoing monthly infusions due to end stage 
liver disease that was unrelated to drug administration (Fig. 1, Supple-
mentary Table 1). 
3.2. Study participant 1 
The first study subject received a prenatal diagnosis of NPC1. Fetal 
ascites was noted at the 24-week ultrasound. DNA extracted from am-
niotic fluid revealed that the patient was compound heterozygous for 
two pathogenic variants, one maternally inherited (c.2621A > T, p. 
D874V) [9] and the other paternally inherited (c.3557G > A, p. 
R1186H). The patient was born at 39 weeks (Table 1) and admitted to 
the NICU post-delivery. Phototherapy was initiated for hyper-
bilirubinemia. (Fig. 2a, Supplementary Table 2). 
The study was first contacted when he was 4 months of age. Physical 
examination showed hepatosplenomegaly. Abdominal ultrasound 
revealed cirrhosis and a hyperechoic lesion within segment 4, which was 
thought to represent a cholesterol deposit. AFP was elevated at 23,135 
Table 1 
Demographics, genotype, and clinical summary of NPC patients.   
Patient A Participant 1 Participant 2 Participant 3 
Demographics 
Sex Female Male Male Male 
Race/Ethnicity Southeast Asian White/Hispanic White/Hispanic White 
Estimated gestational age 38 3/7 weeks 39 weeks 33 6/7 weeks 33 3/7 weeks 
Birth weight 2630 g 2899 g 2495 g 2125 g 
Birth length 47.1 cm 50 cm 45.5 cm 45 cm 
Occipitofrontal 
circumference 
32 cm 34 cm 31.5 cm 30 cm 
Age at study enrollment Shortly after birth 4 months old 2 months old 5 months old  
Genetic information 
NPC1cDNA change c.3503G > A c.1301C >
G 
c.2621A > T c.3557G > A c.2872C > T c.451_452del c.332dupG c.1210C > T 
Protein change p.C1168Y p.P434R p.D874V p.R1186H p.R958X p.S151FfsX18 p. 
A1108RfsX13 
p.R404W 
Mutation types Likely 
pathogenic 
VUS Pathogenic Pathogenic Pathogenic Pathogenic Pathogenic Likely 
pathogenic 









Method of detection Cholestasis gene panel Parental carrier screening, targeted 
gene sequencing 
Whole genome sequencing Cholestasis gene panel  
Clinical information 
Abdominal ascites + + fetal – – 
Neonatal jaundice + + + +
Hepatomegaly + + + +
Splenomegaly + + + – 
Vertical supranuclear 
gaze palsy 
– – + –  
Fig. 1. Biomarkers, liver function tests (LFTs) and bilirubin concentrations in Patient A. C-triol: cholestane-3β,5α,6β-triol C-triol. PPCS: N-palmitoyl-O- 
phosphocholineserine. 
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ng/mL (nl 8-87 ng/mL). He was started on IV 2HPBCD per study pro-
tocol at age 4 months. A repeat AFP level at 6 months demonstrated 
downward trending levels to 1171 ng/mL. Direct bilirubin decreased to 
0.3 mg/dL (nl 0.1–0.3) two weeks after his first infusion and remained 
within normal limits after the 6-week infusion completing the first phase 
of the protocol (Fig. 2, Supplementary Table 2). He met criteria to 
transition to the second Phase of the study and was treated monthly with 
IV 2HPBCD for six months. At the end of the study, his AST and ALT 
improved but remained elevated. His bile acid marker was similarly 
improved but elevated. 
The liver size at the end of the study by ultrasound was 8.7 cm, which 
was improved from initiation of the study. (Table 2) Finally, OAE 
remained within normal limits for the duration of the study. 
3.3. Study participant 2 
The second study participant was a male infant born at 33 6/7 weeks 
gestational age. Pregnancy was complicated by preterm labor and 
breech presentation. He was delivered by C-section with a birth weight 
of 2.495 kg (Table 1). The patient was admitted to the NICU for three 
weeks due to poor weight gain and persistent elevated bilirubin and liver 
transaminases. (Fig. 2b., Supplementary Table 3) Whole genome 
sequencing revealed that the patient was compound heterozygous for 
two pathogenic variants in NPC1, one maternally inherited (c.2872C >
T, p.Arg958Ter) and the other paternally inherited (c.451_452del, p. 
Ser151PhefsTer18)e. 
The study was first contacted when he was 2 months old. This patient 
initiated study treatment at age 2 months of age and completed Phase I 
of the protocol receiving two infusions of IV 2HPBCD per week for 6 
weeks. After Phase I his liver function studies showed improvement 
(Fig. 2b, Supplementary Table 3). After completion of the monthly in-
fusions, his AST remained somewhat elevated at 75 units/L (nl 10–60 
units/L) and ALT 48 units/L (nl 5–50 units/L). His bile acid B was 101 
ng/mL. His liver by ultrasound measured 8.10 cm which was improved 
from baseline at the initiation of the study (Supplementary Table 5) The 
participant's OAE remained unchanged for the duration of the study. 
3.4. Study participant 3 
The third study participant was a 5-month-old boy born at 33 3/7 
weeks post-menstrual age due to preterm labor. His birthweight was 
2125 g. He developed jaundice in the NICU which provoked a workup. 
Genetic testing showed two heterozygous variants of NPC1: c.3320dupG 
(p.A1109RfsX13 and a c.1210C > T (p.R404W) that were classified as 
Fig. 2. Biomarkers, liver function tests (LFTs) and bilirubin concentrations in clinical trial subjects. A) Study participant 1; B) Study participant 2; C) Study 
participant 3. Gray shading indicates second phase of the study, when dosing frequency changed from twice weekly (approximately every four days) to once monthly. 
TCG: 3β,5α,6β-trihydroxycholan-24-oyl glycine. Study participant 2 experienced an acute change in liver function studies at month 2 (dose 14) which corresponded 
temporally with a viral infection. Scale of y-axis differs between Figs. 1 and 2. 
M. Reynolds et al.                                                                                                                                                                                                                              
Molecular Genetics and Metabolism Reports 28 (2021) 100772
5
likely pathogenic. 7-KC was elevated at 1.446 nmol/mL (ref <0.10), C- 
triol was elevated at 0.300 nmol/L (ref <0.07), and PPCS was within 
normal limits at 0.010 nmol/mL (ref <0.10). The oxysterol profile is 
consistent with a biochemical diagnosis of NPC. 
The study was first contacted about this patient when he was 4 
months old. He presented 1 month later (Fig. 2c, Supplementary 
Table 4) and initiated the study drug at age 5 months. After Phase I his 
lab values improved. His liver was 8.3 cm, which was decreased from 
baseline 9.0 cm. After completion of the monthly infusions, his AST 
remained somewhat elevated at 77 units/L (nl 10–60 units/L) and ALT 
65 units/L (nl 5–50 units/L). His final bile acid B was 87.9. His liver by 
ultrasound measured 10 cm (Supplementary Table 5). The participant's 
OAE remained unchanged for the duration of the study. 
3.5. Subjects not enrolled 
Twelve additional children were pre-screened for enrollment. Four 
children did not meet inclusion criteria: one was excluded based on age 
(10 years old), and three were excluded because they did not have liver 
disease. Two children received off-site drug via an eIND: one because the 
study had not yet opened for enrollment, and one because the child was 
too unstable to travel. Two children were in critical condition and suc-
cumbed to their illness prior to traveling to our institution or receiving 
treatment. Finally, four children contacted the study team, but after 
conversations with the team, families opted not to participate in the 
study. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 
2) pandemic was a factor in the decision not to travel to St. Louis for the 
study for two of these four potential participants. 
3.6. Adverse events 
Patients have not had adverse events related to the study drug. 
Adverse events occurring during the study have included PICC line er-
ythema, elevated transaminases, fever, cough, and viral exanthem. 
4. Discussion 
Four patients with NPC1 have received IV 2HPBCD at our institution. 
Three patients are alive and had improvement in TCG and their liver 
function studies, and bilirubin levels during the course of study partic-
ipation. Neonatal liver disease typically resolves in infants with NPC1 
who survive the acute phase, so it is difficult to determine whether IV 
2HPBCD impacted the natural disease course. This study was limited by 
a lack of control group due to concerns at the time that this would be 
practically and ethically challenging. 
NPC1 encodes a large membrane glycoprotein, which localizes to the 
late endosome [10]. NPC2 encodes a small soluble lysosomal protein 
that binds cholesterol. Both proteins are found in the late endosomal/ 
lysosomal (LE/LY) system. NPC1 and NPC2 protein are thought to 
facilitate egress of cholesterol from LE/LY to other parts of the cell [11]. 
This accumulation of cholesterol then results in glycosphingolipid 
accumulation [12]. These mutations lead to impairment in processing 
and utilizing cholesterol causing cholesterol storage and alterations of 
sphingomyelin metabolism in extra neural tissues [1]. The result of 
NPC1 and NPC2 mutations is that cholesterol does not exit the endocytic 
pathway but accumulates within lysosomes. 
This accumulation causes half of patients to experience prolonged 
neonatal cholestatic icterus and progressive hepatosplenomegaly 
[9,13]. In most cases, the icterus spontaneously improves, but the hep-
atosplenomegaly may persist. Among 10% of patients, the icterus 
quickly worsens, and the patients develop liver failure. These patients 
typically die before the age of 6 months.12 We cannot yet predict which 
patients will recover from their liver disease versus which patients will 
progress to liver failure [9]. Of the patients who survive liver failure, all 
eventually experience progressive and fatal neurologic disease [14]. 
Classic neurologic symptoms include cerebellar ataxia, dysarthria, 
dysphagia, dementia, and vertical supranuclear gaze palsy [14]. 
A study using intrathecal 2HPBCD/VTS-270 administration for NPC1 
patients found that monthly 2HPBCD in 14 patients with NPC had 
decreased disease progression compared to matched natural history 
cohorts.15 Seven patients experienced no progression or mild improve-
ment, while all patients included in a natural history cohort progressed 
over 18 months [15]. 
The natural history of NPC has been studied. On review of 52 NPC 
patients, 34 (65%) had liver disease. In this study, 3 infants had a pro-
gressive course during infancy which led to their demise, 4 had pro-
gressive liver disease, while 15 had mild persistent liver disease [9]. 
Similarly, in another review of patients in the UK with NPC, 47 of 94 
patients had neonatal presentation, 4 of these patients died before age 1 
[5]. A study from the same group in 2015 found that the severe neonatal 
onset form of NPC was most commonly associated with death from liver 
disease in 3 of 6 patients.13 In a NPC database, 87/136 patients returned 
a questionnaire, and 52% reported neonatal jaundice with splenomegaly 
(35%), hepatomegaly (31%) and ascites (19%). In our cohort, patient A 
had evidence of progressive liver disease, and died in infancy. While 
PPCS decreased in this baby after treatment, all biomarkers remained 
very high, and the child ultimately progressed to liver failure and death. 
All three infants (patients 1–3) enrolled in our study have mild persistent 
liver disease. None of these infants have evidence of progressive liver 
disease. On the contrary, there was an improvement in cholestasis in all 
three infants and hepatomegaly (liver size on ultrasound) in all three 
infants enrolled in our study. In addition, there were no signs indicating 
development of portal hypertension or ascites on ultrasound or duplex 
studies. The clinical significance of the persistent liver disease in NPC is 
usually overshadowed by the development of severe neurologic disease. 
Table 2 
Abdominal ultrasound reports.  
Patient A  
Baseline End treatmenta 
Spleen size 6.90 cm 9.00 cm 
Liver size 7.10 cm 10.00 cm 
Body weight 2.60 kg 4.00 kg 
Body length 51.5 cm 54.0 cm   
Study Subject 1: VTS-270-WU01  
Baseline End phase 1 End phase 2 
Spleen size 8.56 cm 9.00 cm 10.4 cm 
Spleen volume 88.4 cc 98.1 cc 177.2 cc 
Liver size 9.55 cm 9.60 cm 8.7 cm 
Body weight 6.97 kg 7.90 kg 11.6 kg 
Body length 67.0 cm 69.8 cm 78.2 cm   
Study Subject 2: VTS-270-WU02  
Baseline End phase 1 End phase 2 
Spleen size 7.96 cm 8.40 cm 11.20 cm 
Spleen volume 84.2 cc 71.8 cc 127.0 cc 
Liver size 8.83 cm 8.70 cm 8.10 cm 
Body weight 3.33 kg 4.40 kg 8.60 kg 
Body length 50.5 cm 54.5 cm 72.8 cm   
Study Subject 3: VTS-270-WU03  
Baseline End phase 1 End phase 2 
Spleen size 6.70 cm 7.10 cm 7.60 cm 
Spleen volume 67.0 cc 58.6 cc 69.2 cc 
Liver size 9.00 cm 8.30 cm 10.00 cm 
Body weight 5.78 kg 7.10 kg 9.20 kg 
Body length 61.5 cm 62.4 cm 72.7 cm  
a Measured by abdominal MRI. 
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In the aforementioned study, liver disease did not correlate with the 
onset of neurologic disease, which starts at mean of 4.5 years [16]. We 
did see an increase in splenomegaly in all three infants in our study [17]. 
The exact mechanism of 2HPBCD's effect is unknown. One theory is 
that 2HPBCD reaches the LE/LY system and can facilitate movement of 
stored cholesterol. It is believed that 2HPBCD can replace NPC1 or NPC2 
or it may complex with other proteins and cause cholesterol flux in other 
ways, e.g. promoting autophagic flux [18]. In so doing, it may lead to 
normalized trafficking and clearance of accumulated cholesterol and 
glycosphingolipids [19–21]. 
Because NPC is a cholesterol storage disorder, it results in an accu-
mulation of cholesterols. The most important plasma biomarkers for 
NPC include oxysterols (C-triol and 7-KC), TCG, and PPCS, all of which 
are significantly elevated in NPC. However, we do not know how any of 
these markers change over time. Oxysterols are generated from choles-
terol trapped in lysosome due to oxidative stress, and TGC is a metab-
olite of C-triol. The biosynthesis of PPCs is unknown, and it is very likely 
that its elevation is secondary to accumulation of cholesterol in lyso-
some. Cholesterol is significantly elevated in liver in NPC disease, and 
liver is a major organ to produce oxysterols and TCG. Clearance of 
accumulated cholesterol in lysosome of liver by 2HPBCD leads to 
decrease of these NPC biomarkers [4]. Finally, 3 beta, 5 alpha, 6 beta- 
trihydroxycholanic acid (bile acid B) is a metabolite of oysterol 
cholestane-3 beta,5 alpha,6 beta-triol (COT) and is elevated in NPC. Our 
group developed the bile acid B screening as a more suitable way to 
screen infants for possible NPC using dried blood spots [22]. This assay 
is now being piloted as a newborn screen in NY State. 
In summary, three patients have been enrolled in this open-label 
Phase I/II clinical trial for infants with liver disease due to NPC. One 
additional patient was treated with an emergency IND, but succumbed 
to liver disease. No patient has had significant adverse events related to 
the drug. At last follow up, all surviving patients had TCG, a marker of 
cholesterol storage, improved from the initial visit. Liver transaminases 
improved all subjects. Liver size decreased in all subjects. Additional 
subject accrual and study are needed to determine whether neonatal 
liver disease due to NPC may improve during treatment with 2HPBCD. 
Acknowledgements 
Funding source is U01 HD090845, Grants from the National 
Niemann-Pick Disease Foundation, the NIH CTSA Grant # UL1 
TR000448, Together Strong NPC Foundation, the University of Penn-
sylvania Orphan Disease Center (MDBR-17-124-NPC), the intramural 
research program of NICHD, NIH. 
Research reported in this publication was supported by the Wash-
ington University Institute of Clinical and Translational Sciences grant 
UL1TR002345 from the National Center for Advancing Translational 
Sciences (NCATS) of the National Institutes of Health and the Eunice 
Kennedy Shriver National Institute of Child Health & Human Develop-
ment of the National Institutes of Health under Award Number P50 
HD103525 to the Intellectual and Developmental Disabilities Research 
Center at Washington University. The content is solely the responsibility 
of the authors and does not necessarily represent the official view of the 
NIH. 
The authors wish to acknowledge the support of the I2 WUSM ICS 
and NCI Cancer Center Support Grant P30 CA091842, Siteman 
Comprehensive Cancer Center for supporting the REDCap clinical data 
capture service as a research resource at WUSM. 
Mallinckrodt provided the drug. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.ymgmr.2021.100772. 
References 
[1] M.T. Vanier, Niemann-Pick disease type C, Orphanet J. Rare Dis. (2010), https:// 
doi.org/10.1186/1750-1172-5-16. 
[2] S. Boenzi, F. Deodato, R. Taurisano, B.M. Goffredo, C. Rizzo, C. Dionisi-Vici, 
Evaluation of plasma cholestane-3 β,5 α,6 β -triol and 7-ketocholesterol in inherited 
disorders related to cholesterol metabolism, J. Lipid Res. 57 (2016), https://doi. 
org/10.1194/jlr.M061978. 
[3] R. Sidhu, P. Kell, D.J. Dietzen, N.Y. Farhat, A.N.D. Do, F.D. Porter, E. Berry-Kravis, 
J. Reunert, T. Marquardt, R. Giugliani, C.M. Lourenço, R.Y. Wang, N. Movsesyan, 
E. Plummer, J.E. Schaffer, D.S. Ory, X. Jiang, Application of a glycinated bile acid 
biomarker for diagnosis and assessment of response to treatment in Niemann-pick 
disease type C1, Mol. Genet. Metab. 131 (2020), https://doi.org/10.1016/j. 
ymgme.2020.11.005. 
[4] R. Sidhu, P. Kell, D.J. Dietzen, N.Y. Farhat, A.N.D. Do, F.D. Porter, E. Berry-Kravis, 
C.H. Vite, J. Reunert, T. Marquardt, R. Giugliani, C.M. Lourenço, O. Bodamer, R. 
Y. Wang, E. Plummer, J.E. Schaffer, D.S. Ory, X. Jiang, Application of N-palmitoyl- 
O-phosphocholineserine for diagnosis and assessment of response to treatment in 
Niemann-Pick type C disease, Mol. Genet. Metab. 129 (2020), https://doi.org/ 
10.1016/j.ymgme.2020.01.007. 
[5] J. Imrie, S. Dasgupta, G.T.N. Besley, C. Harris, L. Heptinstall, S. Knight, M. 
T. Vanier, A.H. Fensom, C. Ward, E. Jacklin, C. Whitehouse, J.E. Wraith, The 
natural history of Niemann-Pick disease type C in the UK, J. Inherit. Metab. Dis. 
(2007), https://doi.org/10.1007/s10545-006-0384-7. 
[6] E.M. Fernandez-Valero, A. Ballart, C. Iturriaga, M. Lluch, J. Macias, M.T. Vanier, 
M. Pineda, M.J. Coll, Identification of 25 new mutations in 40 unrelated Spanish 
Niemann-Pick type C patients: Genotype-phenotype correlations, Clin. Genet. 68 
(2005), https://doi.org/10.1111/j.1399-0004.2005.00490.x. 
[7] D. Sitarska, A. Ługowska, Laboratory diagnosis of the Niemann-Pick type C disease: 
an inherited neurodegenerative disorder of cholesterol metabolism, Metab. Brain 
Dis. (2019), https://doi.org/10.1007/s11011-019-00445-w. 
[8] R. Mashima, M. Maekawa, A. Narita, T. Okuyama, N. Mano, Elevation of plasma 
lysosphingomyelin-509 and urinary bile acid metabolite in Niemann-Pick disease 
type C-affected individuals, Mol. Genet. Metab. Rep. (2018), https://doi.org/ 
10.1016/j.ymgmr.2018.03.005. 
[9] J. Imrie, L. Heptinstall, S. Knight, K. Strong, Observational cohort study of the 
natural history of Niemann-Pick disease type C in the UK: A 5-year update from the 
UK clinical database, BMC Neurol. (2015), https://doi.org/10.1186/s12883-015- 
0511-1. 
[10] M.E. Higgins, J.P. Davies, F.W. Chen, Y.A. Ioannou, Niemann-pick C1 is a late 
endosome-resident protein that transiently associates with lysosomes and the 
trans-Golgi network, Mol. Genet. Metab. (1999), https://doi.org/10.1006/ 
mgme.1999.2882. 
[11] S.R. Pfeffer, NPC intracellular cholesterol transporter 1 (NPC1)-mediated 
cholesterol export from lysosomes, J. Biol. Chem. (2019), https://doi.org/ 
10.1074/jbc.TM118.004165. 
[12] C.D. Davidson, N.F. Ali, M.C. Micsenyi, G. Stephney, S. Renault, K. Dobrenis, D. 
S. Ory, M.T. Vanier, S.U. Walkley, Chronic cyclodextrin treatment of murine 
Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid 
storage and disease progression, PLoS One (2009), https://doi.org/10.1371/ 
journal.pone.0006951. 
[13] M.T. Vanier, D.A. Wenger, M.E. Comly, R. Rousson, R.O. Brady, P.G. Pentchev, 
Niemann-Pick disease group C: clinical variability and diagnosis based on defective 
cholesterol esterification: a collaborative study on 70 patients, Clin. Genet. (1988), 
https://doi.org/10.1111/j.1399-0004.1988.tb03460.x. 
[14] D. Solomon, A.C. Winkelman, D.S. Zee, L. Gray, J. Büttner-Ennever, Niemann-Pick 
type C disease in two affected sisters: Ocular motor recordings and brain-stem 
neuropathology, in, Ann. N. Y. Acad. Sci. (2005), https://doi.org/10.1196/ 
annals.1325.041. 
[15] E. Berry-Kravis, J. Chin, A. Hoffmann, A. Winston, R. Stoner, L. LaGorio, 
K. Friedmann, M. Hernandez, D.S. Ory, F.D. Porter, J.A. O’Keefe, Long-term 
treatment of Niemann-Pick type C1 disease with Intrathecal 2-Hydroxypropyl- 
β-Cyclodextrin, Pediatr. Neurol. (2018), https://doi.org/10.1016/j. 
pediatrneurol.2017.12.014. 
[16] D.A. Kelly, B. Portmann, A.P. Mowat, S. Sherlock, B.D. Lake, Niemann-Pick disease 
type C: diagnosis and outcome in children, with particular reference to liver 
disease, J. Pediatr. (1993), https://doi.org/10.1016/S0022-3476(05)81695-6. 
[17] W.S. Garver, G.A. Francis, D. Jelinek, G. Shepherd, J. Flynn, G. Castro, C. 
W. Vockley, D.L. Coppock, K.M. Pettit, R.A. Heidenreich, F.J. Meaney, The national 
Niemann-pick C1 disease database: report of clinical features and health problems, 
Am. J. Med. Genet. Part A (2007), https://doi.org/10.1002/ajmg.a.31735. 
[18] S. Dai, A.E. Dulcey, X. Hu, C.A. Wassif, F.D. Porter, C.P. Austin, D.S. Ory, 
J. Marugan, W. Zheng, Methyl-β-cyclodextrin restores impaired autophagy flux in 
Niemann-Pick C1-deficient cells through activation of AMPK, Autophagy (2017), 
https://doi.org/10.1080/15548627.2017.1329081. 
[19] B. Liu, S.D. Turley, D.K. Burns, A.M. Miller, J.J. Repa, J.M. Dietschy, Reversal of 
defective lysosomal transport in NPC disease ameliorates liver dysfunction and 
neurodegeneration in the npc1− /− mouse, Proc. Natl. Acad. Sci. U. S. A. (2009), 
https://doi.org/10.1073/pnas.0810895106. 
M. Reynolds et al.                                                                                                                                                                                                                              
Molecular Genetics and Metabolism Reports 28 (2021) 100772
7
[20] B. Liu, H. Li, J.J. Repa, S.D. Turley, J.M. Dietschy, Genetic variations and 
treatments that affect the lifespan of the NPC1 mouse, J. Lipid Res. (2008), https:// 
doi.org/10.1194/jlr.M700525-JLR200. 
[21] C.H. Vite, J.H. Bagel, G.P. Swain, M. Prociuk, T.U. Sikora, V.M. Stein, P. O’Donnell, 
T. Ruane, S. Ward, A. Crooks, S. Li, E. Mauldin, S. Stellar, M. De Meulder, M.L. Kao, 
D.S. Ory, C. Davidson, M.T. Vanier, S.U. Walkley, Intracisternal cyclodextrin 
prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick 
type C1 disease, Sci. Transl. Med. (2015), https://doi.org/10.1126/ 
scitranslmed.3010101. 
[22] X. Jiang, R. Sidhu, L. Mydock-McGrane, F.F. Hsu, D.F. Covey, D.E. Scherrer, 
B. Earley, S.E. Gale, N.Y. Farhat, F.D. Porter, D.J. Dietzen, J.J. Orsini, E. Berry- 
Kravis, X. Zhang, J. Reunert, T. Marquardt, H. Runz, R. Giugliani, J.E. Schaffer, D. 
S. Ory, Development of a bile acid-based newborn screen for Niemann-pick disease 
type C, Sci. Transl. Med. (2016), https://doi.org/10.1126/scitranslmed.aaf2326. 
M. Reynolds et al.                                                                                                                                                                                                                              
